Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 6/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.45 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5233877 | 0.90 | RXRA (0.50) | POLBHCRTR1HCRTR2NR1H3CYP11B1 | |
| SCHEMBL30436883 | 0.84 | HCRTR1 (0.51) | HCRTR1HCRTR2CYP11B1CYP11B2KCNK3 | |
| SCHEMBL25218080 | 0.81 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP11B1CYP11B2KCNK3 | |
| SCHEMBL529916 | 0.81 | POLB (0.60) | POLBRXFP1KDM4EKMT2A | |
| SCHEMBL4302001 | 0.80 | KMT2A (0.49) | POLBNR1H3RXFP1NR1H2KDM4E | |
| SCHEMBL14893567 | 0.80 | KCNK3 (0.49) | HCRTR1HCRTR2CYP11B1CYP11B2KCNK3 | |
| SCHEMBL9001638 | 0.78 | POLB (0.75) | POLBNR1H3KDM4EKMT2A | |
| SCHEMBL3550257 | 0.77 | HCRTR1 (0.63) | HCRTR1HCRTR2CYP11B1CYP11B2KCNK3 | |
| SCHEMBL530230 | 0.77 | TSHR (0.63) | POLBHCRTR1HCRTR2KDM4EKMT2A | |
| SCHEMBL29374906 | 0.77 | KDM4E (0.53) | CYP11B1CYP11B2KCNK3KCNK9RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | POLB 2100/4885HCRTR1 4580/4885HCRTR2 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.